natgillin/translations-raw huggingface dataset:
Women who could become pregnant should use adequate contraception such as oral contraceptives, diaphragm plus spermicide, intrauterine device (also known as a coil) during treatment and for three months after the last SCENESSE implantation.
Ženske v rodni dobi morajo med zdravljenjem z zdravilom SCENESSE in tri mesece po njegovi zadnji vsaditvi uporabljati ustrezno kontracepcijo, kot so peroralna kontracepcija, diafragma v kombinaciji s spermicidom ali maternični vložek.
Women who could become pregnant should use appropriate contraception during treatment with Extavia.
Ženske, ki lahko zanosijo, morajo v času zdravljenja z zdravilom Extavia uporabljati ustrezno kontracepcijo.
Women who could become pregnant should use contraception during treatment with dulagutide.
Ženske v rodni dobo morajo med zdravljenjem z dulaglutidom uporabljati kontracepcijo.
Women who could become pregnant should use contraception during treatment with dulagutide.
Ženske v rodni dobo morajo med zdravljenjem z dulagutidom uporabljati kontracepcijo.
women who could become pregnant, unless they take all of the necessary steps to ensure that they are not pregnant before treatment and that they do not become pregnant during or soon after treatment; patients who are unable to follow or to comply with the requirement to use contraceptives.
ženske, ki bi lahko zanosile, razen če storijo vse potrebno za zagotovitev, da ne bodo zanosile pred zdravljenjem, kakor tudi da ne bi zanosile med samim zdravljenjem ali kmalu po njem; bolniki, ki niso zmožni upoštevati zahtev po uporabi kontracepcijskih sredstev ali ravnati v skladu z njimi.
Women who could get pregnant should use contraception to stop them getting pregnant during treatment.
Ženske v rodni dobi morajo uporabljati kontracepcijo za preprečevanje zanositve med zdravljenjem.
Women who could get pregnant should use effective contraception during treatment with Myocet and for 6 months after treatment.
Ženske, ki bi lahko zanosile, naj med zdravljenjem z zdravilom Myocet in 6 mesecev po zdravljenju uporabljajo učinkovito kontracepcijo.
Women who might become pregnant are advised to use effective contraception during treatment.
Ženskam, ki bi lahko zanosile, med zdravljenjem priporočamo uporabo učinkovite kontracepcijske metode.
Women who might become pregnant are advised to use effective contraception during treatment.
Ženskam, ki lahko zanosijo, v času zdravljenja priporočamo uporabo učinkovite kontracepcijske metode.
Women who might get pregnant are advised to use highly effective contraception during treatment and for up to two weeks after ending treatment.
Ženskam, ki bi lahko zanosile, se med zdravljenjem in še dva tedna po zaključku zdravljenja priporoča uporaba zelo učinkovite kontracepcijske metode.
Women who received canakinumab during pregnancy should be instructed to inform the baby’s healthcare professional before any vaccinations are given to their newborn infant.
Ženske, ki v času nosečnosti prejemajo kanakinumab, morajo o tem obvestiti otrokovega zdravnika, preden novorojenček prejme katerokoli cepivo.
Women with a history of tubal disease are at risk of ectopic pregnancy, whether the pregnancy is obtained by spontaneous conception or with fertility treatments.
Pri ženskah z boleznijo jajcevodov v anamnezi obstaja tveganje zunajmaternične nosečnosti ne glede na to, ali pride do zanositve spontano ali z zdravljenjem neplodnosti.
Women with anovulation (including polycystic ovarian syndrome)
Ženske z anovulacijo (vključno s sindromom policističnih jajčnikov)
Women with anovulation resulting from severe LH and FSH deficiency
Ženske z anovulacijo zaradi hudega pomanjkanja LH in FSH
Women with breast cancer who took Prolia also had higher bone density in the lower spine after one year.
Ženske z rakom dojke, ki so jemale zdravilo Prolia, so po enem letu imele večjo gostoto kosti v spodnjem delu hrbtenice.
Women with HIV should not breast-feed their infants because babies can be infected with HIV through their breast milk.
Z virusom HIV okužene ženske ne smejo dojiti, kajti otrok se lahko preko materinega mleka okuži z virusom HIV.
Women with hypertriglyceridaemia, or a family history thereof, may be at an increased risk of pancreatitis when using COCs.
Ženske s hipertrigliceridemijo ali hipertrigliceridemijo v družinski anamnezi imajo lahko med jemanjem COC povečano tveganje za nastanek pankreatitisa.
Women with hypertriglyceridaemia, or a family history thereof, may be at an increased risk of pancreatitis when using COCs.
Ženske s hipertrigliceridemijo ali hipertrigliceridemijo v družinski anamnezi imajo lahko med jemanjem KPK povečano tveganje za nastanek pankreatitisa.
Women with hypertriglyceridaemia, or a family history thereof, may be at an increased risk of pancreatitis when using combined hormonal contraceptives.
Pri ženskah s hipertrigliceridemijo ali hipertrigliceridemijo v družinski anamnezi, ki jemljejo kombinirane hormonske kontraceptive, lahko obstaja zvečano tveganje za pankreatitis.
Women with pre-existing hypertriglyceridaemia should be followed closely during treatment with oestrogens, since rare cases of large increases of plasma triglycerides leading to pancreatitis have been reported with oestrogen therapy in this condition.
Ženske z obstoječo hipertrigliceridemijo je treba med zdravljenjem z estrogeni skrbno opazovati, ker so v redkih primerih pri zdravljenju bolnic v takem stanju z estrogenom poročali o velikem zvečanju trigliceridov v plazmi, ki je vodilo v pankreatitis.
Women – keep using contraception for 2 months after.
Ženske – kontracepcijo uporabljajte še 2 meseca po koncu zdravljenja.
Woodberry flavour Neohesperidin-dihydrochalcone Magnesium stearate
Okus gozdne jagode Neohesperidin dihidrokalkon Magnezijev stearat
Work surfaces and material which have potentially been in contact with Glybera must be decontaminated with appropriate virucidal disinfectants with activity for non-enveloped viruses (such as hypochlorite and chlorine releasers) for at least 10 minutes.
Delovne površine in material, ki so morda prišli v stik z zdravilom Glybera, je treba za vsaj 10 minut dekontaminirati z ustreznimi virucidnimi dezinfekcijskimi sredstvi, ki delujejo na viruse brez ovojnice (kot so sredstva, ki sproščajo hipoklorit in klor).
Worsening
poslabšanje
Worsening (including bradykinesia, dyskinesia, gait abnormality) and an increased incidence or severity of tremor have been observed in patients with dementia associated with Parkinson’s disease (see section 4.8).
Pri bolnikih z demenco in s Parkinsonovo boleznijo so opazili poslabšanje (ki vključuje bradikinezijo, diskinezijo in motnje drže) ter pogostejši in intenzivnejši tremor (glejte poglavje 4.8).
Worsening (including bradykinesia, dyskinesia, gait abnormality) and an increased incidence or severity of tremor have been observed in patients with dementia associated with Parkinson’s disease (see section 4.8).
Pri bolnikih z demenco v povezavi s Parkinsonovo boleznijo so opazili poslabšanje (ki vključuje bradikinezijo, diskinezijo in motnje drže) in povečano pojavnost in intenzivnost tremorja (glejte poglavje 4.8).
Worsening heart failure†
poslabšanje srčnega popuščanja
worsening hypertension worsening albuminuria
poslabšanje hipertenzije poslabšanje albuminurije
worsening kidney function (defined as a persistent [reproduced over at least 2 weeks] 25% reduction in reciprocal serum creatinine during treatment [from end of titration to last on-drug visit])
poslabšanja delovanja ledvic (opredeljenega kot trdovratnega [ponovljeno v vsaj 2 tednih] 25-% zmanjšanje recipročnega kreatinina v serumu med zdravljenjem [od konca titriranja do zadnjega obiska z jemanjem zdravila])
Worsening of a condition called dermatomyositis (seen as a skin rash accompanying muscle weakness)
poslabšanje dermatomiozitisa (ki se kaže kot kožni izpuščaj, ki spremlja šibkost mišic)
Worsening of a condition called dermatomyositis (seen as a skin rash accompanying muscle weakness).
poslabšanje dermatomiozitisa (ki se kaže kot kožni izpuščaj, ki spremlja šibkost mišic),
Worsening of a condition called myasthenia gravis, a rare disease which causes muscle weakness (frequency unknown).
Poslabšanje stanja, imenovanega miastenija gravis, redke bolezni, ki povzroči šibkost mišic (pogostnost neznana).
Worsening of depression, Crohn’s disease and ulcerative colitis have been associated with COC use.
Z uporabo KPK je bilo povezano poslabšanje depresije, Crohnove bolezni in ulceroznega kolitisa.
Worsening of diabetic metabolic state
poslabšanje metaboličnega stanja pri sladkorni bolezni
Worsening of disease has been reported with beta-blockers in patients suffering from psoriasis.
Pri bolnikih s psoriazo so poročali o poslabšanju bolezni zaradi uporabe antagonistov adrenergičnih receptorjev beta.
Worsening of endogenous depression, of epilepsy, of Crohn’s disease and of ulcerative colitis has been reported during COC use.
Med uporabo KPKS so poročali o poslabšanju endogene depresije, epilepsije, Crohnove bolezni in ulceroznega kolitisa.
Worsening of epilepsy (possible more frequent and/or severe seizures)
poslabšanje epilepsije (večja pogostnost napadov in/ali hujši napadi)
Worsening of existing high blood pressure
poslabšanje že zvišanega krvnega tlaka
Worsening of general state of health, generally feeling unwell and weak
poslabšanje splošnega zdravstvenega stanja, splošno slabo počutje in občutek oslabelosti,
Worsening of high blood pressure
poslabšanje visokega krvnega tlaka
Worsening of liver function in patients with advanced liver disease has been reported in some patients with CF receiving lumacaftor/ivacaftor.
O poslabšanju funkcije jeter pri bolnikih z napredovalo boleznijo jeter so poročali pri nekaterih bolnikih s CF, ki so prejemali lumakaftor/ivakaftor.
Worsening of PAH
Poslabšanje PAH
Worsening of Parkinson’s disease
Poslabšanje Parkinsonove bolezni
Worsening of Parkinson’s disease, seizure, tremor, somnolence
poslabšanje Parkinsonove bolezni, konvulzije, tremor, somnolenca
Worsening of psoriasis (thickened patches of red skin)
poslabšanje psoriaze (zadebeljene lise rdeče kože);
worsening of rheumatic conditions; pains or difficulties in passing urine.
poslabšanje revmatičnega stanja, bolečine ali težave pri uriniranju.
worsening of rheumatoid arthritis
poslabšanje revmatoidnega artritisa
Worsening of seizures
poslabšanje epileptičnih napadov, premalo aktivna ščitnica.
Worsening of skin redness, flushing or burning feeling of the skin:
Poslabšanja pordelosti, vročinskih oblivov ali pekočega občutka na koži:
worsening of symptoms of dermatomyositis1)
poslabšanje simptomov dermatomiozitisa1)
Worsening of symptoms.
Poslabšanje simptomov.
worsening of the diabetic metabolic state
poslabšanje metaboličnega stanja pri sladkorni bolezni
Worsening of the diabetic metabolic state
poslabšanje metaboličnega stanja pri sladkorni bolezni,
Worsening of vision
poslabšanje vida,
worsening or new onset of psoriasis (including palmoplantar pustular psoriasis 1),
poslabšanje ali pojav psoriaze (vključno s palmoplantarno pustularno psoriazo)1)
worsening or new onset of psoriasis (including palmoplantar pustular psoriasis)1),
poslabšanje ali pojav psoriaze (vključno s palmoplantarno pustularno psoriazo)1),
worsening or new onset of psoriasus (including palmplantar pustular psoriasis)1),
poslabšanje ali pojav psoriaze (vključno s palmplantarno pustularno psoriazo)1)
Worsening renal function
Zmanjšanje delovanja ledvic
Worsening vision
poslabšanje vida,
Worst National Cancer Institute Common Terminology Criteria for Adverse Events Grade.
a najvišja stopnja po dokumentu Skupni terminološki kriteriji za neželene dogodke (Common Terminology Criteria for Adverse Events, CTCAE) nacionalnega onkološkega inštituta ZDA (National Cancer Institute, NCI)
Worst NCI Grade per patient (%)
Bolniki z največjo stopnjo po NCI (%)
Wort
(hypericum
Wort.
šentjanževko.
Wound care after debridement
Nega očiščene rane
Wound complication
zaplet v zvezi z rano
Wound complication
zapleti ran
Wound complication*
Zapleti pri rani
Wound complication, open wound
zapleti na rani, odprta rana.
Wound complication, secretion, bruising (contusion), pain after procedure
hujšanje, zapleti na rani, izloček, podplutba (kontuzija), bolečine po postopku.
Wound complication, Wound secretion, Contusion, Procedural pain
zapleti na rani, sekrecija iz rane, kontuzija, bolečina, povezana s postopkom
Wound complications
Zapleti z ranami
Wound complications
Zapleti z rano
Wound dehiscence, Wound secretion
pooperativni zapleti z rano,
Wound drainage
drenaža rane
Wound haemorrhage
krvavitev iz rane
Wound haemorrhage
krvavitev rane
Wound haemorrhage Vascular pseudoaneurysm
krvavitev iz rane, žilna psevdoanevrizma
Wound haemorrhage, Traumatic haemorrhage
krvavitev iz rane, travmatska krvavitev
Wound healing complication
Zapleti s celjenjem rane
Wound healing complicationsb,d, Exfoliative dermatitis,
zapleti pri celjenju ranb,d, eksfoliativni dermatitis,
wound infection
okužba rane;
wound infection
okužbe ran,
Wound infection, Erysipelas,
okužba rane, erizipel,
Wound infections
okužbe ran
Wound infections and abscesses
Okužene rane in abscesi
Wound opening (soft and hard tissues)
odpiranje rane (mehka in trda tkiva),
wound pain, wound opening or accumulation of fluid at surgical site
bolečina na rani, odpiranje rane ali kopičenje tekočine na mestu kirurškega posega,
Wounds on the legs (leg ulcers), and modification of liver function,
Rane na nogah (ulkusi na nogah), spremembe jetrne funkcije.
Wounds taking longer to heal
počasnejše celjenje ran
Wounds taking longer to heal
počasnejše celjenje ran,
Wounds that are more likely to get tetanus infection are burns, fractures, deep wounds or wounds that have soil, dust, horse manure or wood splinters in them.
Rane, ki se še posebno rade okužijo s tetanusom so opekline, zlomi, globoke rane ali rane onesnažene z zemljo, prahom, konjskimi iztrebki ali lesenimi trskami.
Wounds that are more likely to get tetanus infection are burns, fractures, deep wounds or wounds that have soil, dust, horse manure or wood splinters in them.
Rane, ki se še posebno rade okužijo s tetanusom, so opekline, zlomi, globoke rane ali rane onesnažene z zemljo, prahom, konjskimi iztrebki ali lesenimi trskami.
Wounds that have difficulties healing
rane, ki se slabo celijo
Wounds which heal slowly or not at all: Uncommon (may affect up to 1 in 100 people) - this is when a scar has trouble healing or staying closed, or if a healed wound re-opens.
Rane, ki se celijo počasi ali se sploh ne celijo: občasno (pojavijo se lahko pri največ 1 od 100 oseb) – rana se težko celi, težko ostane zaprta, ali pa se zaceljena rana znova odpre.
Wounds with areas of full thickness and deep burn should be autografted as soon as possible after NexoBrid debridement.
Na rane s predeli globokih in subdermalnih opeklin je treba presaditi avtotransplantate takoj, ko je mogoče po čiščenju z zdravilom NexoBrid.
Wounds with areas of full-thickness and deep burn should be autografted as soon as possible after NexoBrid debridement.
Na rane s predeli globokih in subdermalnih opeklin je treba presaditi avtotransplantate takoj, ko je mogoče po čiščenju z zdravilom NexoBrid.
Wrap the patient’s treated hand with a soft, bulky, gauze dressing.
Povijte bolnikovo zdravljeno roko z mehko, obsežno obvezo iz gaze.
WRAPPER LABEL ON MULTIPACKS WRAPPED IN FOIL (INCLUDING BLUE BOX)
NALEPKA NA FOLIJSKEM OVITKU SKUPNEGA PAKIRANJA (VKLJUČNO Z MODRIM OKENCEM)
WRAPPER LABEL ON MULTIPACKS WRAPPED IN FOIL (INCLUDING BLUE BOX)
ZAVOJI Z VEČ ŠKATLAMI, ZAVITIMI V FOLIJO (VKLJUČENI PODATKI ZA “BLUE BOX”)
WRAPPER LABEL ON MULTIPACKS WRAPPED IN FOIL COMPRISING 2 MONTHLY PACKS, EACH CONTAINING 4 WEEKLY PACKS) (INCLUDING BLUE BOX)
NALEPKA NA OVITKU SKUPNEGA PAKIRANJA, ZAVITEGA V FOLIJO, KI OBSEGA 2 MESEČNI PAKIRANJI, OD KATERIH VSAKO VSEBUJE 4 TEDENSKA PAKIRANJA (VKLJUČNO Z "BLUE BOX" PODATKI)
Wrinkles
imeti gub,
Write down the date of opening on the carton label in the space provided.
Na nalepko škatle kapalnega vsebnika vpišite datum odprtja vsebnika.
Write down the date you open it in the space on each bottle label and box.
Na vsako nalepko na kapalnem vsebniku in na škatlo si zapišite datum odprtja kapalnega vsebnika.
Write down the date you opened it in the space on each bottle label and box
Na vsako nalepko na kapalnem vsebniku in na škatlo si zapišite datum odprtja vsebnika.
Write down the date, time, and specific part of your body where you injected yourself.
Zapišite si datum, čas in predel telesa, kamor ste si vbrizgali zdravilo.
Write down the date, time, dose, site(s) of infusion (to assist in rotating sites) and any reactions after each infusion.
Zapišite datum, uro, mesto(a) infundiranja (kar vam bo v pomoč pri menjavi mest)
Write down what you eat in a food diary, including the calorie and fat content.
Zapišite kaj pojeste v dnevnik prehranjevanja, vključno z vsebnostmi kalorij in maščob.
Write down your doctor or nurse’s instructions:
Zabeležite si navodila zdravnika ali medicinske sestre:
Write down your doctor or nurse’s instructions: Doctor’s office telephone and e-mail: Pharmacist’s telephone:
Zabeležite si navodila zdravnika ali medicinske sestre: Telefon ali e-pošta zdravnikove ordinacije:
Write down your first injection date on a calendar.
Na koledar si vpišite datum vašega prvega injiciranja.
Write the date of expiration of the constituted suspension on the bottle label (the shelf-life of the constituted suspension is 14 days).
Na nalepko plastenke napišite rok uporabnosti pripravljene suspenzije (rok uporabnosti pripravljene suspenzije je 14 dni).
Write the date of expiration of the reconstituted suspension on the bottle label. (The shelf-life of the reconstituted suspension is two months.)
Na nalepko steklenice napišite datum uporabnosti pripravljene suspenzije. (Rok uporabnosti pripravljene suspenzije je dva meseca.)
Write the date of expiry of the constituted suspension on the bottle label (the shelf-life of the constituted suspension is 14 days).
Na nalepko na plastenki napišite rok uporabnosti pripravljene suspenzije (rok uporabnosti pripravljene suspenzije je 14 dni).
Write the date of reconstitution and expiry on the label (expiry is 1 month after reconstitution).
Na nalepko napišite datum rekonstitucije raztopine in rok uporabnosti (rok uporabnosti je 1 mesec po pripravi).
Write the date the inhaler should be discarded on the label in the space provided.
V predvideni prostor na nalepki inhalatorja vpišite datum, do katerega morate inhalator zavreči.
Write the date you opened the foil pouch on the label of the inhaler.
Zabeležite datum odprtja vrečke iz folije na nalepki inhalatorja.
Write the date you opened the foil pouch on the label on the inhaler.
Na nalepko inhalatorja zabeležite datum, ko ste odprli ovoj iz folije.
Write your doctor's details below:
Spodaj vpišite podatke o svojem zdravniku:
Write your doctor’s details below:
Spodaj napišite podatke o svojem zdravniku.
Wrong dose selected.
Nastavljen je bil napačen odmerek.
Wye Valley Business Park, Brecon Road, Hay-on-Wye Hereford - Herefordshire HR3 5PG - United Kingdom
Wye Valley Business Park, Brecon Road, Hay-on-Wye Hereford - Herefordshire HR3 5PG - Velika Britanija
Wyeth BioPharma One Burtt Road Andover Massachusetts 01810 USA
Wyeth BioPharma One Burtt Road Andover Massachusetts 01810 ZDA
x 1 bottles
1 prebodnimi
x 1 bottles.
1 prebodnimi
x 1 dose
Dukoral
x 1 dose x 1 dose
x 1 odmerek x 1 odmerek
x 1 film-coated tablets film-coated tablets
49 x 1 filmsko obloženih tablet 50 filmsko obloženih tablet
x 1 orodispersible tablet in alu/alu perforated unit dose blister, x 1 orodispersible tablets in alu/alu perforated unit dose blisters, 4 x 1 orodispersible tablets in alu/alu perforated unit dose blisters, 8 x 1 orodispersible tablets in alu/alu perforated unit dose blisters.
1 x 1 orodisperzibilna tableta v aluminj/aluminij perforiranem pretisnem omotu za enkratni odmerek, 2 x 1 orodisperzibilna tableta v aluminj/aluminij perforiranem pretisnem omotu za enkratni odmerek, 4 x 1 orodisperzibilna tableta v aluminj/aluminij perforiranem pretisnem omotu za enkratni odmerek, 8 x 1 orodisperzibilna tableta v aluminj/aluminij perforiranem pretisnem omotu za enkratni odmerek.
x 200 mg tablets A.M. x 200 mg tablets P.M. x 200 mg tablets A.M. x 200 mg tablets P.M.
1 x 200-mg tableta zjutraj 2 x 200-mg tableti zvečer
x 3 ml pre-filled pen 5 x 3 ml pre-filled pens x (5 x 3 ml) pre-filled pens
x 3 ml napolnjen injekcijski peresnik 5 x 3 ml napolnjeni injekcijski peresniki x (5 x 3 ml) napolnjeni injekcijski peresniki
X and Y are the days (to be determined) when pre-treatment measurements should be performed.
X in Y sta dneva (ki ju je treba določiti) za izvedbo meritev pred zdravljenjem.
x axis; Months, y axis; Proportion Progression Free, Pazopanib —―— (N = 135) Median 7.4 months; Placebo -------- (N = 67) Median 4.2 months; Hazard Ratio = 0.54, 95 % CI (0.35, 0.84), P < 0.001
os x: meseci, os y: delež brez napredovanja, Pazopanib —―— (n = 135) mediana 7,4 meseca, Placebo—―— (n = 67) mediana 4,2 meseca, Razmerje tveganj = 0,54, 95 % IZ (0,35, 0,84), P < 0,001
x axis; Months, y axis; Proportion Progression Free, Pazopanib —―— (N = 155) Median 11.1 months; Placebo -------- (N = 78) Median 2.8 months; Hazard Ratio = 0.40, 95 % CI (0.27, 0.60), P < 0.0000001
os x: meseci, os y: delež brez napredovanja, Pazopanib —―— (n = 155) mediana 11,1 meseca, Placebo-------- (n = 78) mediana 2,8 meseca, Razmerje tveganj = 0,40, 95 % IZ (0,27, 0,60), P < 0,0000001
x axis; Months, y axis; Proportion Progression Free, Pazopanib —―— (N = 290) Median 9.2 months; Placebo -------- (N = 145) Median 4.2 months; Hazard Ratio = 0.46, 95 % CI (0.34, 0.62), P < 0.0000001
os x: meseci, os y: delež brez napredovanja, Pazopanib —―— (n = 290) mediana 9,2 meseca, Placebo -------- (n = 145) mediana 4,2 meseca, Razmerje tveganj = 0,46, 95 % IZ (0,34, 0,62), P < 0,0000001
x axis; Weeks (Rescue free), y axis; Probability of event
Os x: tedni (brez rešilnega ukrepanja), os y: verjetnost dogodka
X Locked
X Nesproščen
X-rays of children given Strensiq were also compared with similar x-rays available from 16 children who had not received Strensiq (‘historical controls’).
Rentgenske slike otrokov, ki so prejemali zdravilo Strensiq, so primerjali s podobnimi rentgenskimi slikami 16 otrok, ki niso prejeli zdravila Strensiq („pretekli kontrolni podatki“).
X-rays) Do not sterilise
Ne sterilizirajte.
Xadago 50 mg are orange to copper, round, biconcave film-coated tablets of 7 mm diameter with metallic gloss, embossed with “50” on one side of the tablet.
Xadago 50 mg so oranžne do bakrene barve, okrogle, bikonkavne filmsko obložene tablete premera 7 mm s kovinskim sijajem in vtisnjeno jakostjo „50“ na eni strani tablete.
Xadago 50 mg film-coated tablets
Xadago 50 mg filmsko obložene tablete
Xadago 50 mg film-coated tablets Xadago 100 mg film-coated tablets Safinamide
Xadago 50 mg filmsko obložene tablete Xadago 100 mg filmsko obložene tablete Safinamid
Xadago can, therefore, be used safely without any dietary tyramine restrictions.
Zdravilo Xadago se lahko tako varno uporablja brez prehranskih omejitev tiramina.
Xadago has no or negligible influence on the ability to drive and use machines; however you should be cautious about operating hazardous machines or driving, until you are reasonably certain that Xadago does not affect you in any way.
Zdravilo Xadago ne vpliva na sposobnost upravljanja vozil in strojev ali pa je ta vpliv zanemarljiv; kljub temu morate biti pri upravljanju z nevarnimi stroji ali vožnji previdni, dokler ne boste prepričani, da zdravilo Xadago na vas nima nobenega učinka.
Xadago is a medicine that contains the active substance safinamide.
Xadago je zdravilo, ki vsebuje zdravilno učinkovino safinamid.
Xadago is a medicine used to treat Parkinson’s disease, a progressive brain disorder that causes shaking, slow movement and muscular stiffness.
Zdravilo Xadago se uporablja za zdravljenje Parkinsonove bolezni, tj. napredujoče okvare možganov, ki povzroča tresavico, upočasnjeno izvajanje gibov in okorelost mišic.